Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362489332> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W4362489332 abstract "<div>Abstract<p>Chondrosarcomas are inherently resistant to chemotherapy and radiotherapy, pointing to an unmet need for new treatment options. Immune checkpoint inhibitors, which have shown remarkable promise in multiple solid cancer types, have limited efficacy in chondrosarcomas. Mutations in <i>IDH1/2</i> genes, which result in progressive increases in DNA and histone methylation, are observed in 50% of conventional chondrosarcomas, suggesting that epigenetic dysregulation represents a potential barrier for tumor progression and target for therapeutic intervention. Here, we demonstrated that combined treatment of FDA-approved inhibitors of DNA methyltransferases (DNMTs) 5-aza-2′-deoxycytidine (5-aza), and histone deacetylases (HDACs) suberanilohydroxamic acid (SAHA) impaired the proliferation of chondrosarcoma cell lines <i>in vitro</i> and in xenograft studies. Transcriptomic analysis reveals that chondrosarcoma cells treated with 5-aza and SAHA markedly elevated the expression of IFN-stimulated genes including PD-L1, indicating that these epigenetic drugs induced a potent innate immune response. We demonstrated that 5-aza and SAHA resulted in both genomic and epigenomic instability, as shown by elevated DNA damage response and derepression of retrotransposons, respectively, which in turn activated pattern recognition receptors (PRRs) and the downstream IFN signaling pathways. Importantly, the cytotoxic effects of 5-aza and SAHA can be rescued by depletion of PRRs such as cGAS and MAVS, and potentiated by depletion of the RNA-editing enzyme ADAR1. Together, our results demonstrate preclinical activity of combined DNMT and HDAC inhibition against chondrosarcomas and suggest that targeted epigenetic therapies could represent a new therapeutic approach in the treatment of chondrosarcomas, and this is being tested in an ongoing clinical trial (NCT04340843).</p></div>" @default.
- W4362489332 created "2023-04-05" @default.
- W4362489332 creator A5006913373 @default.
- W4362489332 creator A5031842757 @default.
- W4362489332 creator A5036120936 @default.
- W4362489332 creator A5041344060 @default.
- W4362489332 creator A5061625997 @default.
- W4362489332 creator A5071074966 @default.
- W4362489332 creator A5083916650 @default.
- W4362489332 date "2023-04-03" @default.
- W4362489332 modified "2023-10-18" @default.
- W4362489332 title "Data from Growth Inhibition and Induction of Innate Immune Signaling of Chondrosarcomas with Epigenetic Inhibitors" @default.
- W4362489332 doi "https://doi.org/10.1158/1535-7163.c.6543247" @default.
- W4362489332 hasPublicationYear "2023" @default.
- W4362489332 type Work @default.
- W4362489332 citedByCount "0" @default.
- W4362489332 crossrefType "posted-content" @default.
- W4362489332 hasAuthorship W4362489332A5006913373 @default.
- W4362489332 hasAuthorship W4362489332A5031842757 @default.
- W4362489332 hasAuthorship W4362489332A5036120936 @default.
- W4362489332 hasAuthorship W4362489332A5041344060 @default.
- W4362489332 hasAuthorship W4362489332A5061625997 @default.
- W4362489332 hasAuthorship W4362489332A5071074966 @default.
- W4362489332 hasAuthorship W4362489332A5083916650 @default.
- W4362489332 hasBestOaLocation W43624893322 @default.
- W4362489332 hasConcept C104317684 @default.
- W4362489332 hasConcept C121912465 @default.
- W4362489332 hasConcept C136449434 @default.
- W4362489332 hasConcept C150194340 @default.
- W4362489332 hasConcept C190727270 @default.
- W4362489332 hasConcept C203014093 @default.
- W4362489332 hasConcept C2780737395 @default.
- W4362489332 hasConcept C33288867 @default.
- W4362489332 hasConcept C41091548 @default.
- W4362489332 hasConcept C502942594 @default.
- W4362489332 hasConcept C54355233 @default.
- W4362489332 hasConcept C552990157 @default.
- W4362489332 hasConcept C64927066 @default.
- W4362489332 hasConcept C86803240 @default.
- W4362489332 hasConcept C8891405 @default.
- W4362489332 hasConcept C91965660 @default.
- W4362489332 hasConceptScore W4362489332C104317684 @default.
- W4362489332 hasConceptScore W4362489332C121912465 @default.
- W4362489332 hasConceptScore W4362489332C136449434 @default.
- W4362489332 hasConceptScore W4362489332C150194340 @default.
- W4362489332 hasConceptScore W4362489332C190727270 @default.
- W4362489332 hasConceptScore W4362489332C203014093 @default.
- W4362489332 hasConceptScore W4362489332C2780737395 @default.
- W4362489332 hasConceptScore W4362489332C33288867 @default.
- W4362489332 hasConceptScore W4362489332C41091548 @default.
- W4362489332 hasConceptScore W4362489332C502942594 @default.
- W4362489332 hasConceptScore W4362489332C54355233 @default.
- W4362489332 hasConceptScore W4362489332C552990157 @default.
- W4362489332 hasConceptScore W4362489332C64927066 @default.
- W4362489332 hasConceptScore W4362489332C86803240 @default.
- W4362489332 hasConceptScore W4362489332C8891405 @default.
- W4362489332 hasConceptScore W4362489332C91965660 @default.
- W4362489332 hasLocation W43624893321 @default.
- W4362489332 hasLocation W43624893322 @default.
- W4362489332 hasOpenAccess W4362489332 @default.
- W4362489332 hasPrimaryLocation W43624893321 @default.
- W4362489332 hasRelatedWork W1572803005 @default.
- W4362489332 hasRelatedWork W1993254391 @default.
- W4362489332 hasRelatedWork W2042241638 @default.
- W4362489332 hasRelatedWork W2062262581 @default.
- W4362489332 hasRelatedWork W2182398254 @default.
- W4362489332 hasRelatedWork W2615094618 @default.
- W4362489332 hasRelatedWork W2889146372 @default.
- W4362489332 hasRelatedWork W2927098937 @default.
- W4362489332 hasRelatedWork W2987996809 @default.
- W4362489332 hasRelatedWork W3032511498 @default.
- W4362489332 isParatext "false" @default.
- W4362489332 isRetracted "false" @default.
- W4362489332 workType "article" @default.